334476-68-5

Upstream product

• 452-63-1 2-Bromo-5-fluorotoluene 
• 334477-07-5 (4-fluoro-2-methylphenyl)oxoacetic acid methyl ester 
• 30897-90-6 (2-methyl-4-fluorophenyl)magnesium bromide 
• 290297-43-7 3,5-bis(trifluoromethyl)-α-methyl-N-methylbenzylamine 
• 334477-68-8 3-(4-fluoro-2-methylphenyl)-piperazin-2-one 
• 30071-93-3 3,5-bis(trifluoromethyl)phenyl methyl ketone 
• 1333317-69-3 N-(1-(3,5-bis(trifluoromethyl) phenyl)ethylidene)methanamine 
• 334477-08-6 3-(4-fluoro-2-methylphenyl)-5,6-dihydro-1H-pyrazin-2-one 

Relevant academic research and scientific papers

Composition Comprising An NK-1 Receptor Antagonist And An SSRI For The Treatment Of Tinnitus And Hearing Loss

The present invention relates to methods for treating a subject suffering from tinnitus, hearing loss, or tinnitus and hearing loss comprising administering to the subject an effective amount of an NK1 receptor antagonist alone, or in combination with an

Synthesis of the NK1 receptor antagonist GW597599. Part 1: development of a scalable route to a key chirally pure arylpiperazine

GW5975991 is a novel NK-1 antagonist currently under investigation for the treatment of CNS disorders and emesis. The initial synthetic route devised from the medicinal chemistry one, used several hazardous reagents, gave low yields, and produced high lev

Chemical compounds

The invention relates to piperazine derivatives, to processes for their preparation, to pharmaceutical compositions containing them, and to their medical use. The novel compounds are antagonists of tachykinins, including substance P and other neurokinins.